KDM4A has been shown to promote GBM growth by activating the AKT-mTOR pathway through upregulation of 3-phosphoinositide-dependent protein kinase 1 (PDK1), an effect antagonized by rapamycin, an mTOR inhibitor [216]. Here, MTOR is linked to glioblastoma.